Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

NCT02525939 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

6147

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Coronary Syndrome

Interventions

DRUG: dalcetrapib
DRUG: Placebo

Sponsor

DalCor Pharmaceuticals

Collaborators

[object Object]
[object Object]
[object Object]